Home LiteratureArticle Details
PMID: 10223912 Published · ppublish English Comparative Study Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Antimycobacterial activities of isoxyl and new derivatives through the inhibition of mycolic acid synthesis.

Antimicrobial agents and chemotherapy ·Vol. 43 ·No. 5 ·1999-05-00 ·Pages 1042-51

Phetsuksiri B, Baulard AR, Cooper AM, Minnikin DE, Douglas JD, Besra GS, Brennan PJ

Abstract

Isoxyl (ISO), a thiourea (thiocarlide; 4, 4'-diisoamyloxythiocarbanilide), demonstrated potent activity against Mycobacterium tuberculosis H37Rv (MIC, 2.5 micrograms/ml), Mycobacterium bovis BCG (MIC, 0.5 microgram/ml), Mycobacterium avium (MIC, 2.0 microgram/ml), and Mycobacterium aurum A+ (MIC, 2.0 microgram/ml), resulting in complete inhibition of mycobacteria grown on solid media. Importantly, a panel of clinical isolates of M. tuberculosis from different geographical areas with various drug resistance patterns were all sensitive to ISO in the range of 1 to 10 microgram/ml. In a murine macrophage model, ISO exhibited bactericidal killing of viable intracellular M. tuberculosis in a dose-dependent manner (0.05 to 2.50 microgram/ml). The selective action of ISO on mycolic acid synthesis was studied through the use of [1, 2-14C]acetate labeling of M. tuberculosis H37Rv, M. bovis BCG, and M. aurum A+. At its MIC for M. tuberculosis, ISO inhibited the synthesis of both fatty acids and mycolic acids (alpha-mycolates by 91.6%, methoxymycolates by 94.3%, and ketomycolates by 91.1%); at its MIC in M. bovis BCG, ISO inhibited the synthesis of alpha-mycolates by 87.2% and that of ketomycolates by 88.5%; and the corresponding inhibitions for M. aurum A+ were 87.1% for alpha-mycolates, 87.2% for ketomycolates, and 86.5% for the wax-ester mycolates. A comparison with isoniazid (INH) and ethionamide (ETH) demonstrated marked similarity in action, i.e., inhibition of the synthesis of all kinds of mycolic acids. However, unlike INH and ETH, ISO also inhibited the synthesis of shorter-chain fatty acids. ISO showed no acute toxicity against primary macrophage cell cultures as demonstrated by diminution of redox activity. A homologous series of ISO derivatives were synthesized. Most derivatives were as effective or more effective than the parent compound in the agar proportion assay. Thus, these thioureas, like INH and ETH, specifically inhibit mycolic acid synthesis and show promise in counteracting a wide variety of drug-sensitive and -resistant strains of M. tuberculosis.

MeSH Terms
Antitubercular Agents/pharmacology Ethionamide/pharmacology Isoniazid/pharmacology Mycobacterium/drug effects,growth & development,metabolism Mycolic Acids/antagonists & inhibitors,metabolism Phenylthiourea/analogs & derivatives,pharmacology Thiourea/analogs & derivatives,pharmacology
Chemicals
Antitubercular Agents Mycolic Acids thiocarlide Phenylthiourea Thiourea Ethionamide Isoniazid
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Phetsuksiri B
Department of Microbiology, Colorado State University, Fort Collins, Colorado 80523-1677, USA.
Baulard A R
Cooper A M
Minnikin D E
Douglas J D
Besra G S
Brennan P J
References (43)
43 references, click to expand
  1. Antimycobacterial action of thiolactomycin: an inhibitor of fatty acid and mycolic acid synthesis.
    Antimicrob Agents Chemother. 1996 Dec;40(12):2813-9 PMID: 9124847
  2. Catalase and peroxidase in mycobacteria. Possible relationship to the mode of action of isoniazid.
    Am Rev Respir Dis. 1960 Jan;81:68-78 PMID: 13845182
  3. In vitro bactericidal and in vivo therapeutic activities of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 1996 Feb;40(2):426-8 PMID: 8834891
  4. Relationship between the uptake of isoniazid and its action on in vivo mycolic acid synthesis in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 1972 Dec;2(6):438-41 PMID: 4207759
  5. Drug-resistant strains of Mycobacterium tuberculosis exhibit a range of virulence for mice.
    Infect Immun. 1995 Feb;63(2):741-3 PMID: 7822053
  6. Biochemical and genetic data suggest that InhA is not the primary target for activated isoniazid in Mycobacterium tuberculosis.
    J Infect Dis. 1996 Nov;174(5):1085-90 PMID: 8896513
  7. Susceptibility of a panel of virulent strains of Mycobacterium tuberculosis to reactive nitrogen intermediates.
    Infect Immun. 1997 Apr;65(4):1189-95 PMID: 9119450
  8. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis.
    Nature. 1992 Aug 13;358(6387):591-3 PMID: 1501713
  9. Results of monotherapy with Isoxyl in untreated pulmonary tuberculosis cases of different difficulties and Isoxyl in routine-therapy.
    Antibiot Chemother. 1970;16:96-104 PMID: 5535617
  10. Peroxidase-mediated oxidation of isoniazid.
    Antimicrob Agents Chemother. 1985 Mar;27(3):399-403 PMID: 3922297
  11. Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid.
    Science. 1998 Jun 5;280(5369):1607-10 PMID: 9616124
  12. Mycolic acid patterns of some species of Mycobacterium.
    Arch Microbiol. 1984 Oct;139(2-3):225-31 PMID: 6517656
  13. Effect of isoniazid on the in vivo mycolic acid synthesis, cell growth, and viability of Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 1972 Jul;2(1):29-35 PMID: 4208567
  14. Chemotherapy of experimental tuberculosis. V. Isonicotinic acid hydrazide (nydrazid) and related compounds.
    Am Rev Tuberc. 1952 Apr;65(4):357-64 PMID: 14903503
  15. Selective action of isoniazid on the synthesis of cell wall mycolates in mycobacteria.
    Ann N Y Acad Sci. 1974 May 10;235(0):426-38 PMID: 4212333
  16. USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results.
    Ann Intern Med. 1990 Mar 15;112(6):397-406 PMID: 2155569
  17. Inhibition by isoniazid of synthesis of mycolic acids in Mycobacterium tuberculosis.
    J Gen Microbiol. 1970 Sep;63(1):41-8 PMID: 5500025
  18. Control mechanisms for fatty acid synthesis in Mycobacterium smegmatis.
    Adv Enzymol Relat Areas Mol Biol. 1977;45:1-84 PMID: 21523
  19. Tuberculosis in patients with human immunodeficiency virus infection.
    N Engl J Med. 1991 Jun 6;324(23):1644-50 PMID: 2030721
  20. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis.
    Science. 1994 Jan 14;263(5144):227-30 PMID: 8284673
  21. A clinical trial of thiocarlide (4-4' diisoamyloxythiocarbanilide).
    Tubercle. 1966 Sep;47(3):283-8 PMID: 5339425
  22. Effects of ethionamide and isoxyl on mycolic acid synthesis in Mycobacterium tuberculosis BCG.
    J Gen Microbiol. 1971 Jun;66(3):379-80 PMID: 4999216
  23. [Monotherapy with isoxyl-DAT in cases of tuberculosis under hospital care].
    Prax Pneumol. 1966 Apr;20(4):202-6 PMID: 5954242
  24. Clinical experience with thiocarlide (Isoxyl).
    Antibiot Chemother. 1970;16:117-23 PMID: 5535608
  25. Clinical experiences in cases of primary tuberculosis with tuberculostaticum Isoxyl.
    Antibiot Chemother. 1970;16:108-16 PMID: 5316199
  26. The structure and function of the isoniazid target in M. tuberculosis.
    Res Microbiol. 1996 Jan-Feb;147(1-2):36-43 PMID: 8761720
  27. Thiolactomycin, a new antibiotic. III. In vitro antibacterial activity.
    J Antibiot (Tokyo). 1982 Apr;35(4):401-10 PMID: 6980215
  28. Fatty acid synthases from Mycobacterium phlei.
    Methods Enzymol. 1975;35:84-90 PMID: 1121296
  29. A review of the action of isoniazid.
    Am Rev Respir Dis. 1969 May;99(5):729-49 PMID: 4306211
  30. Agar disk elution method for susceptibility testing of Mycobacterium marinum and Mycobacterium fortuitum complex to sulfonamides and antibiotics.
    Antimicrob Agents Chemother. 1983 Oct;24(4):486-93 PMID: 6651277
  31. Site of inhibitory action of isoniazid in the synthesis of mycolic acids in Mycobacterium tuberculosis.
    J Lipid Res. 1975 Jul;16(4):308-17 PMID: 806645
  32. The 7H11 medium for the cultivation of mycobacteria.
    Am Rev Respir Dis. 1968 Aug;98(2):295-6 PMID: 4299186
  33. Regulation of fatty acid biosynthesis in Escherichia coli.
    Microbiol Rev. 1993 Sep;57(3):522-42 PMID: 8246839
  34. Tuberculosis in developing countries: burden, intervention and cost.
    Bull Int Union Tuberc Lung Dis. 1990 Mar;65(1):6-24 PMID: 2190653
  35. Sterilization of tubercle bacilli by isonicotinic acid hydrazide and the incidence of variants resistant to the drug in vitro.
    Am Rev Tuberc. 1952 Jun;65(6):765-7 PMID: 14924201
  36. Multidrug-resistant tuberculosis.
    Ann Intern Med. 1992 Aug 1;117(3):257-9 PMID: 1296597
  37. Mycolic acid synthesis: a target for ethionamide in mycobacteria?
    Antimicrob Agents Chemother. 1992 Jun;36(6):1316-21 PMID: 1416831
  38. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis.
    Science. 1998 Jan 2;279(5347):98-102 PMID: 9417034
  39. Biochemistry and molecular genetics of cell-wall lipid biosynthesis in mycobacteria.
    Mol Microbiol. 1997 Apr;24(2):263-70 PMID: 9159514
  40. Enzymatic characterization of the target for isoniazid in Mycobacterium tuberculosis.
    Biochemistry. 1995 Jul 4;34(26):8235-41 PMID: 7599116
  41. Tuberculosis: commentary on a reemergent killer.
    Science. 1992 Aug 21;257(5073):1055-64 PMID: 1509256
  42. Isoniazid inhibition of mycolic acid synthesis by cell extracts of sensitive and resistant strains of Mycobacterium aurum.
    Antimicrob Agents Chemother. 1991 Jun;35(6):1035-9 PMID: 1656850
  43. The new tuberculosis.
    N Engl J Med. 1992 Mar 5;326(10):703-5 PMID: 1736110
Article Info
Journal
Antimicrobial agents and chemotherapy
Abbr.
Antimicrob Agents Chemother
ISSN
0066-4804
Published
1999-05-00
Pages
1042-51
Language
English
Region
United States
NLM ID
0315061
PMCID
PMC89109
Subset
IM
Grants
NIAID NIH HHS · AI-38087 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]